Chromeno[4,3,2-de]isoquinolines as Potent Dopamine Receptor Ligands
A compound developed by Purdue University researchers, dinoxyline(8,9-dihydroxy-1,2,3,11b-tetragydrichromeno[4,3,2-de]isoquinoline), provides a novel class of therapeutic agents for any disorder that can be treated by drugs affecting dopamine receptors. Where dihydrexidine is ten-fold D1:D2 selective and dinapsoline is five-fold D1:D2 selective, dinoxyline has an equally high affinity for both D1 and D2 receptors. This is surprising considering the structure of this new compound in comparison to related work with other dopamine agonists. The unexpected result suggests that dinoxyline may bind to the D2 receptor in another way, which could translate into unanticipated therapeutic benefits.
Useful in treating certain cognitive disorders and dementiaPotent anti-hypertensive effects Provides novel strategies to treat schizophrenia and drug addiction
Pharmaceutical Industry
David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology
United States
6,916,832
美国
